Alterity Therapeutics' (ASX: ATH) phase 2 clinical trial nears, commercialisation plans continue for MSA drug (w/ David Stamler)

Small Caps - A podcast by Small Caps

Alterity Therapeutics (ASX: ATH) chief executive officer Dr David Stamler joins Small Caps to discuss the company's lead drug candidate...